3Nimgaonkar M, Kemp A, Jancia J, et al. A combination of CD34 selection and complement-mediated immunopurging (anti-CD15monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells[J]..J Hematother, 1996,5(1):39-48.
4Raffi S, Shapiro F, Petten gell R, et al. Human bone marrow microvessel endothelial cells support long- term proliferation and differentition of myeloid and megakaryocytic progenitors [J]. Blood ,1995 , 86:3353.
5Hildebrandt M, Serke S, Meyer O, et al.Immunomagnetic selection of CD +34 cells:factors influencing component purity and yield [J]. Transfusion,2000, 40 (5):507 -512.
6Swihart A H, Mikrut J M, Ketterson J B,et al. Atomic force microscopy of the erythrocyte membrane skeleton[J]. J Microsc,2001, 204(3):212-225.
1[4]Steward A K, Imrie K, Eating A, et al. Optimizing the CD34 + Thy-1 + stem cell content of peripheral blood collections [ J ]. Exp Hematol, 1995, 23: 1619.
2[5]Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estima tion of circulating hematopoietic progenitors for autologous tranplantation in cancer patients[J]. Blood, 1991, 77:400.
3[6]Mayol A S, Vital J B, Llodra A G, et al. CD34+ cell dose and CD33 sudsets: collection and engraftment kinetics in autologous perioheral blood stem cells transplantation[J]. Haematologica, 1998; 83:48.
4[7]Weaver C H, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 + oontent of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy[J]. Blood, 1995, 86:3961.
5[8]Fritsch G, Emminger W, Buchinger P, et al. CD34-positive cell progen itors in peripgeral blood correlate with colony-forming capacity[J ]. ExpHematol, 1991, 19: 1079.
6[9]Welssman I V. Translating stem and progenitor cell biology to the clin ic: Barriers and opportunities[J]. Science, 2000; 287, 1442.
7[10]Barnett D, Granger V, Storie I, et al. Quality assessment of CD34+ stem cell enumeration: experience of the United Kingdom National External Quality Assessment Scheme (UK NEQAS) using a unique stable whole blood preparation[J ]. Br J Haematol, 1998; 102: 553.
8[11]To L B, Haylock D N, Simmons P J, et al. The biology and uses of blood stem cells[J]. Blood, 1997, 89:2233.
9[12]Barnett D, Janossy G, Lukenko A, et al. Guideline for the flow cyto metric enumeration of CD34+ heamatopoietic stem cells[J]. Clin LabHaem, 1999; 21:301.
10[13]Krause D S, Fackler M J, Civin C I, et al. CD34: Structure, biology, and clinical utility[J]. Blood, 1996,87:1.
